TrialAdvances in therapy2025

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.

Rafael Fonseca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.